CJC-1295 / Ipamorelin Blend
Technical Monograph
The CJC-1295 and Ipamorelin combination is a synergistic research compound designed to maximize endogenous growth hormone (GH) secretion via complementary GHRH analog and GH secretagogue pathways.
Mechanism of Action
CJC-1295 (a GHRH analog) provides sustained baseline stimulation of the pituitary, while Ipamorelin (a ghrelin mimetic) induces pulsatile secretagogue action, mimicking physiological release patterns observed in preclinical data.
Pharmacological Detail
CJC-1295 binds to GHRH receptors to increase GH synthesis, while Ipamorelin acts on GHS-R1a receptors to trigger immediate release. Together, they may bypass the inhibitory effects of somatostatin in preclinical models.
Pharmacodynamics
The blend establishes a dual-mechanism environment, where GH output is modulated via two distinct biochemical pathways.
Pharmacokinetics
CJC-1295 (Mod GRF 1-29) has a short half-life (~30 min), while Ipamorelin lasts ~2 hours. DAC versions of CJC-1295 can extend half-life to 6-8 days.
Preclinical Observations & In Vitro Data
Published data indicates single applications can increase mean GH levels 2 to 10-fold and modulate IGF-1 levels 1.5 to 3-fold for extended durations in study models.
Abstract Highlights
- Synergistic GH pulse amplitude elevation documented
- Sustained 24-hour baseline GH levels observed in study models
- High selectivity with minimal cortisol modulation reported
- Metabolic pathway optimization under investigation
Chemical Specifications
Material Handling & Stability
Strict Notice
THIS COMPOUND IS PRODUCED FOR LABORATORY RESEARCH PURPOSES ONLY. NOT FOR HUMAN CONSUMPTION. MATERIAL DATA SHEETS AND LABORATORY GUIDELINES SHOULD BE CONSULTED PRIOR TO HANDLING.